Transfemoral transcatheter aortic valve replacement for pure aortic regurgitation

Affiliations

¹ Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg, 5020, Salzburg, Austria; Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria. Electronic address: bernhard@wernly.net.
² Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital and Medical Faculty, Cardiovascular Research Institute Düsseldorf, Heinrich-Heine University, Duesseldorf, German.

Comment

Bernhard Wernly et al. Lancet. 2024.

. 2024 Apr 13;403(10435):1420-1421.

doi: 10.1016/S0140-6736(24)00062-X. Epub 2024 Mar 26.

¹ Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg, 5020, Salzburg, Austria; Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria. Electronic address: bernhard@wernly.net.
² Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital and Medical Faculty, Cardiovascular Research Institute Düsseldorf, Heinrich-Heine University, Duesseldorf, German.

No abstract available

Conflict of interest statement

We declare no competing interests.

Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study.
Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, McCabe JM, Satler L, Russo M, Cheng W, George I, Aldea G, Sheridan B, Kereiakes D, Golwala H, Zahr F, Chetcuti S, Yadav P, Kodali SK, Treede H, Baldus S, Amoroso N, Ranard LS, Pinto DS, Leon MB. Vahl TP, et al. Lancet. 2024 Apr 13;403(10435):1451-1459. doi: 10.1016/S0140-6736(23)02806-4. Epub 2024 Mar 26. Lancet. 2024. PMID: 38552656 Clinical Trial.